Department of pediatrics, Assiut University, Assiut, Egypt
Research Article
Randomized Clinical Trial of the Use of Eltrombopag in Children with Aplastic Anemia
Author(s): Jameel Alghaberi*, Eman Fathalla Gad, Mai A Abdelfattah, Mohammed H ghazaly, Khalid A Sanousy, Douaa M Sayed, Shimaa Hosny Hassan and Mervat A M Youssef
Abstract: Severe aplastic anemia is a life - threatening disorder that requires prompt treatment. For children not eligible for Hematopoietic Stem Cell Transplantation (HSCT), the Standard Immunosuppressive Therapy (IST) consisting of Antithymocyte Globulin (ATG) and Cyclosporine (CSA) is the ideal treatment for patients with Severe Aplastic Anemia (SAA). The addition of ELTROMBOPAG (E - PAG) with IST shows good improvement in the response rates, a rise of blood cell counts, and recovery of trilineage hematopoiesis. The purpose of this study was to compare the efficacy and safety of E - PAG combined with CsA and immunosuppressive mono therapy of CsA for treatment in children with SAA.
Method: This was a prospective clinical trial with a patient sample of 20 children diagnosed with SAA. Half of the participants were treated with CsA .. View More»
